![]() ![]() Hryhorowicz M, Zeyland J, Słomski R, Lipiński D. Xenotransplantation: immunological hurdles and progress toward tolerance. In addition, following the methodology described in this study for other xenotransplantation targets may provide an alternative to custom antibody development. Antibody reagents from this study will allow for validation of NLRC5, B2M, MHC-I expression in future research studies. The anti-human antibodies ab117624, ab105411, ab178767, ab2216, and ab75853 cross reacted with cognate proteins in porcine cell lysates. In the present study, the human anti-NLRC5 (ab105411), anti-NLRC5 (ab117624), anti-NLRC5 N-terminal (ab178767), anti-HLA E (ab203082), anti-HLA E (ab135826), anti-HLA E (ab2216) and anti-β 2 M (ab75853) antibodies were examined using immunoblots for porcine cross-reactivity. NLRC5, SLA-I, and B2M are all targets of immune modulation in genetically engineered pigs in xenotransplantation research with the goal to reduce SLA-I expression. SLA-I is a known xenoantigen that causes T cell activation. Swine Leukocyte Antigens (SLAs) are the porcine MHC homologs for human leukocyte antigens. Major histocompatibility complex class I (MHC-I) molecule expression enhancement by nucleotide-binding oligomerization domain (NOD)-like receptor family with a caspase recruitment domain (CARD) containing caspase 5 (NLRC5) is fundamental to understanding porcine xenoantigen presentation. Pigs are especially useful large animal models, however, limited availability of commercially available antibodies for immunoblotting presents a significant obstacle facing preclinical xenotransplantation research. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |